Emily K Bergsland

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint The evolving landscape of neuroendocrine tumors
    Emily K Bergsland
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Semin Oncol 40:4-22. 2013
  2. ncbi request reprint Maximizing the potential of bevacizumab in cancer treatment
    Emily Bergsland
    Department of Medicine, University of California, San Francisco, California 94115, USA
    Oncologist 9:36-42. 2004
  3. ncbi request reprint Vascular endothelial growth factor as a therapeutic target in cancer
    Emily K Bergsland
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisidero, 4th Floor, San Francisco, CA 94115, USA
    Am J Health Syst Pharm 61:S4-11. 2004
  4. ncbi request reprint Update on clinical trials targeting vascular endothelial growth factor in cancer
    Emily K Bergsland
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisidero, 4th Floor, San Francisco, CA 94115, USA
    Am J Health Syst Pharm 61:S12-20. 2004
  5. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
  6. doi request reprint A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA, 94115, USA
    Invest New Drugs 26:463-71. 2008
  7. doi request reprint The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine
    Yu Cheng Wang
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California, 1600 Divisadero Street, A 724, San Francisco, California 94143 1932, USA
    Endocr Relat Cancer 17:283-91. 2010
  8. doi request reprint Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site
    Yu Cheng Wang
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143 1932, USA
    J Surg Res 163:47-51. 2010
  9. ncbi request reprint A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 68:809-16. 2007
  10. doi request reprint Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy
    Derrick Wong
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Pancreas 37:269-74. 2008

Collaborators

Detail Information

Publications31

  1. doi request reprint The evolving landscape of neuroendocrine tumors
    Emily K Bergsland
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Semin Oncol 40:4-22. 2013
    ..Steady progress is anticipated, however, given the unprecedented number of ongoing clinical trials related to NET (including studies focused on symptom control, genetics, imaging, and novel therapies)...
  2. ncbi request reprint Maximizing the potential of bevacizumab in cancer treatment
    Emily Bergsland
    Department of Medicine, University of California, San Francisco, California 94115, USA
    Oncologist 9:36-42. 2004
    ..Ultimately, maximizing the potential value of this agent may require a more thorough understanding of bevacizumab's mechanism of action and the pathways mediating resistance...
  3. ncbi request reprint Vascular endothelial growth factor as a therapeutic target in cancer
    Emily K Bergsland
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisidero, 4th Floor, San Francisco, CA 94115, USA
    Am J Health Syst Pharm 61:S4-11. 2004
    ..The link between angiogenesis and tumor progression and the rationale for targeting VEGF in the treatment of cancer will be discussed. In addition, the various therapeutic approaches to inhibiting VEGF will be reviewed...
  4. ncbi request reprint Update on clinical trials targeting vascular endothelial growth factor in cancer
    Emily K Bergsland
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisidero, 4th Floor, San Francisco, CA 94115, USA
    Am J Health Syst Pharm 61:S12-20. 2004
    ..The clinical trials of vascular endothelial growth factor (VEGF) inhibitors are discussed...
  5. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
    ..Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population...
  6. doi request reprint A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA, 94115, USA
    Invest New Drugs 26:463-71. 2008
    ..The objectives of this study were to determine safety and efficacy in chemotherapy-naive patients with metastatic pancreatic cancer receiving bevacizumab in combination with fixed-dose rate (FDR) gemcitabine and low-dose cisplatin...
  7. doi request reprint The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine
    Yu Cheng Wang
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California, 1600 Divisadero Street, A 724, San Francisco, California 94143 1932, USA
    Endocr Relat Cancer 17:283-91. 2010
    ..We conclude that FEV expression identifies serotonin-producing cells in normal and neoplastic SI and is a novel target for diagnosis of patients with NETs of the SI...
  8. doi request reprint Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site
    Yu Cheng Wang
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143 1932, USA
    J Surg Res 163:47-51. 2010
    ..2. We hypothesized that lack of NKX2.2 expression in BP-TCs might be useful to distinguish BP- from GI-NETs, and evaluated NKX2.2 expression in a larger number of BP-TCs...
  9. ncbi request reprint A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 68:809-16. 2007
    ..We conducted a Phase II nonrandomized trial to evaluate sequential chemotherapy followed by chemoradiation in this patient population...
  10. doi request reprint Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy
    Derrick Wong
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Pancreas 37:269-74. 2008
    ..Serum carbohydrate antigen 19-9 (CA19-9) has never been compared to radiographic objective response as a surrogate for clinical outcomes in patients receiving chemotherapy for metastatic pancreatic cancer...
  11. doi request reprint Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients
    Justin R Parekh
    Division of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA
    Pancreas 41:840-4. 2012
    ..We sought to identify clinicopathological factors that predict nodal disease...
  12. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
    ....
  13. doi request reprint Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Cancer Invest 26:47-52. 2008
    ..We, therefore, evaluated this regimen in patients with gemcitabine-refractory disease...
  14. doi request reprint Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer
    Chloe E Atreya
    Division of Hematology Oncology, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Invest New Drugs 30:2219-25. 2012
    ....
  15. doi request reprint Identification of unknown primary tumors in patients with neuroendocrine liver metastases
    Sam C Wang
    Department of Surgery, Division of Surgical Oncology, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94143 1932, USA
    Arch Surg 145:276-80. 2010
    ..Despite preoperative evaluation, the primary tumor location may remain unknown...
  16. ncbi request reprint Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 24:379-85. 2006
    ..The objectives of this study were to determine safety and efficacy in patients with metastatic pancreatic cancer treated with FDR gemcitabine in combination with low-dose cisplatin...
  17. ncbi request reprint Systemic therapy for advanced carcinoid tumors: where do we go from here?
    A Scott Paulson
    University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Natl Compr Canc Netw 10:785-93. 2012
    ..Moving forward, optimizing patient selection based on clinical features or biomarkers holds promise for identifying individuals most likely to benefit from therapy...
  18. ncbi request reprint Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    Eric K Nakakura
    Department of Surgery, Division of Surgical Oncology, University of California, UCSF Comprehensive Cancer Center, 1600 Divisadero Street, A 724, San Francisco, CA 94143 1932, USA
    Surg Oncol Clin N Am 16:639-51, x. 2007
    ..A proposed treatment algorithm is provided with the aim of providing clinicians with a useful framework for managing these challenging patients. Finally, the rationale for promising investigational therapies is described...
  19. ncbi request reprint Pancreatoblastoma in an adult: case report and review of the literature
    Supriya Rajpal
    University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California 94115, USA
    J Gastrointest Surg 10:829-36. 2006
    ..In addition, our case demonstrates that pancreatoblastomas can be alpha-fetoprotein producing, hormone producing, and enzyme producing when it occurs in adults...
  20. pmc Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    Gabriele Bergers
    Department of Neurological Surgery, University of California, San Francisco Comprehensive Cancer Center, San Francisco, San Francisco, California 94115, USA
    J Clin Invest 111:1287-95. 2003
    ..Thus, combinatorial targeting of receptor tyrosine kinases shows promise for treating multiple stages in tumorigenesis, most notably the often-intractable late-stage solid tumor...
  21. ncbi request reprint Couples therapy at end of life
    David C Mohr
    University of California, San Francisco, CA, USA
    Psychooncology 12:620-7. 2003
    ..While the size of the study precludes generalizing these findings to a larger population, this study supports further exploration of couples therapy as a potentially useful adjunct to end of life care...
  22. ncbi request reprint Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region
    Eric K Nakakura
    Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, CA 94143 1932, USA
    Hematol Oncol Clin North Am 21:457-73; viii. 2007
    ..Advances in our understanding of the molecular mechanisms underlying tumor progression have translated into intense interest in biologically based strategies to treat this disease...
  23. ncbi request reprint Angiogenesis in colorectal cancer: therapeutic implications and future directions
    Jill Allen
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisidero, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Hematol Oncol Clin North Am 18:1087-119, ix. 2004
    ..This article discusses the therapeutic implications and future directions of angiogenesis in colorectal cancer...
  24. doi request reprint Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors
    Yu Cheng Wang
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    Endocr Relat Cancer 16:267-79. 2009
    ..2 functions in immature endocrine cells to control NE differentiation in normal intestine and is expressed in most NE tumors of the gut, and is therefore a novel target of diagnosis for patients with gastrointestinal NE tumors...
  25. ncbi request reprint Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer
    Kshama R Mehta
    Comprehensive Cancer Center, Department of Surgery, University of California San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA
    Clin Cancer Res 11:1791-7. 2005
    ..Identification of molecular markers that predict patients at highest risk for recurrence may help to target further therapy...
  26. ncbi request reprint Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature
    Andrew H Ko
    Division of Hematology and Oncology, University of California, San Francisco, California 94115, USA
    Dig Dis Sci 48:192-6. 2003
  27. ncbi request reprint Anti-angiogenic strategies in gastrointestinal malignancies
    Jonathan Whisenant
    San Francisco Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 6:411-21. 2005
    ..Additional information is needed to identify the diseases and stages most likely to benefit from anti-angiogenic agents and the optimal sequences and therapeutic combinations that should be studied...
  28. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  29. ncbi request reprint Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:4793-9. 2007
    ..We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy...
  30. ncbi request reprint When does the presence of the target predict response to the targeted agent?
    Emily K Bergsland
    J Clin Oncol 24:213-6. 2006
  31. ncbi request reprint Shedding old paradigms: developing viruses to treat cancer
    Emily K Bergsland
    J Clin Oncol 20:2220-2. 2002